Anxiety disorders are a group of psychiatric conditions characterized by excessive fear, worry, or physiological hyperarousal that is disproportionate to the situation and persists over time. Clinically, they are defined not only by the presence of anxiety symptoms but also by their impact on functioning and the presence of maladaptive patterns that maintain distress. In DSM-5-TR, common anxiety disorders include generalized anxiety disorder (GAD), panic disorder, social anxiety disorder, specific phobias, agoraphobia, and separation anxiety disorder. Although anxiety can be a normal adaptive response, pathological anxiety involves altered threat processing, persistent activation of stress systems, and failure of normal fear-learning extinction.
From a mechanistic standpoint, anxiety disorders involve dysregulation across cortico-limbic circuits. The amygdala plays a central role in threat detection and salience attribution, while the prefrontal cortex is implicated in top-down regulation and cognitive control. Functional neuroimaging studies frequently show heightened limbic reactivity and reduced regulatory connectivity during threat cues. Neurotransmitter systems also contribute: GABAergic inhibition is often reduced in anxiety states, facilitating neuronal excitability. Serotonergic pathways modulate mood, anxiety sensitivity, and inhibitory tone, while noradrenergic signaling contributes to arousal and vigilance. Chronic stress can further affect the hypothalamic-pituitary-adrenal (HPA) axis, altering cortisol dynamics and reinforcing maladaptive threat expectations.
Cognitive models emphasize catastrophic misinterpretation of bodily sensations and attentional bias toward threat. For example, in panic disorder, interoceptive cues (e.g., palpitations) may be misread as dangerous, triggering a feedback loop of fear, hyperventilation, and escalating symptoms. In GAD, worry is characterized by repetitive, uncontrollable cognitive rehearsal about potential negative outcomes, often accompanied by intolerance of uncertainty, rumination, and difficulty disengaging from threat-related thoughts. Anxiety can thus be maintained by cognitive avoidance strategies, safety behaviors, and negative reinforcement.
Symptomatically, anxiety disorders may include excessive worry, muscle tension, restlessness, irritability, sleep disturbance, and concentration difficulties; autonomic symptoms such as tachycardia, sweating, tremor, and gastrointestinal discomfort are also common. Panic disorder is distinguished by recurrent unexpected panic attacks, typically accompanied by sudden surges of intense fear with dyspnea, chest discomfort, dizziness, paresthesias, and fear of losing control. Social anxiety disorder centers on fear of scrutiny or embarrassment, with avoidance or distress in social or performance situations.
Diagnosis requires careful clinical assessment. Clinicians evaluate symptom duration, triggers, severity, impairment, and exclusion of substance- or medication-induced symptoms and medical conditions that can mimic anxiety (e.g., hyperthyroidism, pheochromocytoma, arrhythmias, seizure disorders, medication side effects, and substance withdrawal). Differential diagnosis includes depressive disorders, obsessive-compulsive and related disorders, posttraumatic stress disorder (PTSD), adjustment disorders, and schizophrenia-spectrum conditions when anxiety is secondary to psychosis or paranoia. Comorbidities are frequent: anxiety commonly co-occurs with major depressive disorder, substance use disorders, and sometimes attention-deficit/hyperactivity disorder, complicating symptom attribution and treatment selection.
Evidence-based treatment is multimodal and should be tailored to disorder type, severity, patient preference, and comorbidities. First-line psychotherapy for many anxiety disorders includes cognitive behavioral therapy (CBT). CBT targets maladaptive appraisals, threat monitoring, and avoidance. Exposure-based techniques help extinguish conditioned fear responses and correct erroneous predictions of harm, using graded and sustained exposure to feared cues or contexts. For GAD, CBT may include cognitive restructuring, worry postponement, problem-solving strategies, and training in intolerance of uncertainty. For social anxiety disorder, CBT often combines cognitive work with behavioral experiments that test beliefs about negative evaluation.
Pharmacotherapy can be effective, particularly for moderate to severe symptoms or when psychotherapy access is limited. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are widely used first-line options, given their favorable evidence base for anxiety symptom reduction and relapse prevention. Benzodiazepines may provide short-term relief due to rapid anxiolysis via enhanced GABA-A signaling, but they carry risks including sedation, cognitive impairment, falls, dependence, and withdrawal; thus they are generally used selectively, briefly, and with monitoring. Other options in specific contexts may include buspirone for GAD, hydroxyzine as an adjunct, and careful consideration of dosing and time-to-response.
An integrated care approach also emphasizes lifestyle and physiological regulation. Sleep optimization, reduction of stimulants (excess caffeine, decongestants), management of comorbid medical illnesses, and structured activity can reduce baseline arousal. Mindfulness-based strategies may complement CBT by improving attentional control and reducing rumination, though they are typically adjunctive rather than standalone for severe cases.
Prognosis depends on early identification, engagement in evidence-based therapy, and management of comorbidities. Anxiety disorders are often chronic if untreated, but many patients experience substantial improvement with appropriate CBT and/or pharmacotherapy. Longitudinal follow-up supports maintenance strategies, including continued skills practice, relapse prevention planning, and addressing avoidance patterns.
Source: Medscape
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
